We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00474240
First Posted: May 16, 2007
Last Update Posted: February 10, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Aegerion Pharmaceuticals, Inc.
  Purpose
The purpose of this study is to test the effectiveness of the study drug, AEGR-733 alone and in combination with the medication, atorvastatin (Lipitor), on cholesterol in volunteers with moderately high cholesterol.

Condition Intervention Phase
Hypercholesterolemia Drug: Atorvastatin 20 mg Drug: AEGR-733 5 mg Drug: AEGR-733 10 mg Drug: Placebo Drug: AEGR-733 5 mg + atorvastatin 20 mg Drug: AEGR-733 10 mg + atorvastatin 20 mg Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia

Resource links provided by NLM:


Further study details as provided by Aegerion Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Percent Change From Baseline in LDL-C at 8 Weeks [ Time Frame: Atfer 8 weeks on study drug ]

Secondary Outcome Measures:
  • Percent Change From Baseline of Other Lipids [ Time Frame: After 8 weeks of study drug ]

Enrollment: 157
Study Start Date: April 2007
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1 Drug: Placebo
Active Comparator: 2 Drug: Atorvastatin 20 mg
Experimental: 3 Drug: AEGR-733 5 mg
Experimental: 4 Drug: AEGR-733 10 mg
Experimental: 5 Drug: AEGR-733 5 mg + atorvastatin 20 mg
Experimental: 6 Drug: AEGR-733 10 mg + atorvastatin 20 mg

Detailed Description:

Recent studies suggest more intensive cholesterol lowering treatment for people at very high risk of a heart attack, specifically for patients who have heart disease plus major risk factors. Available medications used alone at even the highest approved doses are not expected to reach these new target recommendations for cholesterol in a large number of subjects. Thus, the development of new medications that can provide additional cholesterol lowering may be beneficial.

This study tests the effectiveness of different doses of the study drug, AEGR-733 alone and in combination with the approved cholesterol lowering drug, atorvastatin (Lipitor), on cholesterol. Volunteers will be randomized to one of 6 different study treatments and will take the assigned medication (3 capsules daily) for 8 weeks.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men and women between the ages of 18 and 70 years.
  2. Elevated LDL cholesterol based on risk factors for cardiovascular disease or presence of cardiovascular disease

Exclusion Criteria:

  1. Women who are pregnant, lactating, planning to become pregnant, or women of childbearing potential who have not successfully been using acceptable contraceptive methods over the previous 3 months, e.g., intrauterine device (IUD) and barrier method plus spermicide.
  2. Uncontrolled hypertension
  3. History of chronic kidney problems
  4. History of liver disease
  5. Positive for Hepatitis B or Hepatitis C.
  6. Any major surgical procedure occurring less than 3 months ago
  7. Cardiac insufficiency
  8. History of a malignant cancer (other than basal cell or squamous cell carcinoma of the skin that has been removed) within the previous 5 years.
  9. Regular alcohol use >1 drink per day.
  10. Regular consumers of grapefruit juice, or currently taking the following medications: cyclosporine, itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, and nefazodone.
  11. Use of other cholesterol lowering medications that cannot be stopped.
  12. Heart attack or stroke within the previous 6 months
  13. Diabetes Mellitus
  14. Body mass index (BMI) ≥ 40 kg/m2.
  15. Significant gastrointestinal symptoms, such as irritable bowel syndrome.
  16. Current use of fish oils, niacin, and herbal weight loss products that cannot be stopped.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00474240


Locations
United States, Alabama
Medical Affiliated Research Center
Huntsville, Alabama, United States, 35801
United States, Florida
Jacksonville Center for Clinical research
Jacksonville, Florida, United States, 32205
Jacksonville Center For Clinical Research
Jacksonville, Florida, United States, 32216
Renstar Medical Research
Ocala, Florida, United States, 34471
United States, Georgia
North Georgia Clinical Research
Woodstock, Georgia, United States, 30189
United States, Illinois
Radiant Research
Chicago, Illinois, United States, 60610
United States, Indiana
Medsphere Medical Research Center
Evansville, Indiana, United States, 47714
Midwest Institute for Clinical Research
Indianapolis, Indiana, United States, 46260
United States, Maine
Maine Research Associates
Auburn, Maine, United States, 04210
United States, Maryland
Health Trends Research
Baltimore, Maryland, United States, 21209
United States, North Carolina
Piedmont Medical Research Associates
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
Sterling Research Group
Cincinnati, Ohio, United States, 45246
United States, South Carolina
Coastal Carolina Research Center
Goose Creek, South Carolina, United States, 29445
United States, Texas
Dallas Diabetes and Endocrine Center
Dallas, Texas, United States, 75230
Diabetes and Glandular Disease Research
Dallas, Texas, United States, 78229
United States, Virginia
Hampton Roads Center for Clinical Research
Norfolk, Virginia, United States, 23502
National Clinical Research
Richmond, Virginia, United States, 23294
Sponsors and Collaborators
Aegerion Pharmaceuticals, Inc.
  More Information

Publications:
Responsible Party: Aegerion Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00474240     History of Changes
Other Study ID Numbers: 733-003
First Submitted: May 14, 2007
First Posted: May 16, 2007
Results First Submitted: January 18, 2013
Results First Posted: February 21, 2013
Last Update Posted: February 10, 2014
Last Verified: January 2013

Keywords provided by Aegerion Pharmaceuticals, Inc.:
cholesterol

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Atorvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors


To Top